

Patient Information	Specimen Information	Client Information

COMMENTS:

Test Name	In Range	Out Of Range	Reference Range	Lab
PSA (FREE AND TOTAL)				
PSA, TOTAL	0.3		< OR = 4.0 ng/mL	
PSA, FREE	0.1		ng/mL	
PSA, % FREE	33		>25 % (calc)	
PSA (ng/mL)	Free PSA (%)	Estimated(x) Probability of Cancer (as%)		
0-2.5	(*)	Approx. 1		
2.6-4.0(1)	0-27(2)	24(3)		
4.1-10(4)	0-10	56		
	11-15	28		
	16-20	20		
	21-25	16		
	>or =26	8		
>10(+) N/A		>50		

References: (1) Catalona et al.: Urology 60: 469-474 (2002)
 (2) Catalona et al.: J.Urol 168: 922-925 (2002)
 Free PSA(%) Sensitivity(%) Specificity(%)
 < or = 25 85 19
 < or = 30 93 9
 (3) Catalona et al.: JAMA 277: 1452-1455 (1997)
 (4) Catalona et al.: JAMA 279: 1542-1547 (1998)

(x) These estimates vary with age, ethnicity, family history and DRE results.

(*) The diagnostic usefulness of % Free PSA has not been established in patients with total PSA below 2.6 ng/mL

(+) In men with PSA above 10 ng/mL, prostate cancer risk is determined by total PSA alone.

The Total PSA value from this assay system is standardized against the equimolar PSA standard. The test result will be approximately 20% higher when compared to the WHO-standardized Total PSA (Siemens assay). Comparison of serial PSA results should be interpreted with this fact in mind.

PSA was performed using the Beckman Coulter Immunoassay method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.

PERFORMING SITE:
SPECIMEN: